348 related articles for article (PubMed ID: 14734732)
41. Efficacy of cancer gene therapy in aging: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice.
Provinciali M; Argentati K; Tibaldi A
Gene Ther; 2000 Apr; 7(7):624-32. PubMed ID: 10819579
[TBL] [Abstract][Full Text] [Related]
42. Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency.
Cayeux S; Richter G; Becker C; Beck C; Aicher A; Pezzutto A; Dörken B; Blankenstein T
Eur J Immunol; 1997 Jul; 27(7):1657-62. PubMed ID: 9247574
[TBL] [Abstract][Full Text] [Related]
43. The combined action of IL-15 and IL-12 gene transfer can induce tumor cell rejection without T and NK cell involvement.
Di Carlo E; Comes A; Basso S; De Ambrosis A; Meazza R; Musiani P; Moelling K; Albini A; Ferrini S
J Immunol; 2000 Sep; 165(6):3111-8. PubMed ID: 10975824
[TBL] [Abstract][Full Text] [Related]
44. The induction of in vivo proliferation of long-lived CD44hi CD8+ T cells after the injection of tumor cells expressing IFN-alpha1 into syngeneic mice.
Belardelli F; Ferrantini M; Santini SM; Baccarini S; Proietti E; Colombo MP; Sprent J; Tough DF
Cancer Res; 1998 Dec; 58(24):5795-802. PubMed ID: 9865738
[TBL] [Abstract][Full Text] [Related]
45. Enhanced therapeutic effects against murine colon carcinoma induced by a Colon 26/Ag85A-CD226 tumor cell vaccine.
Li Y; Yang F; Sang L; Zhu J; Han X; Shan F; Li S; Zhai J; Wang D; Lu C; Sun X
Oncol Rep; 2015 Oct; 34(4):1795-804. PubMed ID: 26238268
[TBL] [Abstract][Full Text] [Related]
46. Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals.
Chiyo M; Shimozato O; Yu L; Kawamura K; Iizasa T; Fujisawa T; Tagawa M
Int J Cancer; 2005 Jun; 115(3):437-42. PubMed ID: 15688376
[TBL] [Abstract][Full Text] [Related]
47. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12.
Tannenbaum CS; Wicker N; Armstrong D; Tubbs R; Finke J; Bukowski RM; Hamilton TA
J Immunol; 1996 Jan; 156(2):693-9. PubMed ID: 8543822
[TBL] [Abstract][Full Text] [Related]
48. Enhanced inhibition of tumour growth and metastasis, and induction of antitumour immunity by IL-2-IgG2b fusion protein.
Budagian V; Nanni P; Lollini PL; Musiani P; Di Carlo E; Bulanova E; Paus R; Bulfone-Paus S
Scand J Immunol; 2002 May; 55(5):484-92. PubMed ID: 11975760
[TBL] [Abstract][Full Text] [Related]
49. Therapy of lung metastases through combined vaccination with carcinoma cells engineered to release IL-13 and IFN-gamma.
De Giovanni C; Nicoletti G; Landuzzi L; Rossi I; Astolfi A; Ricci C; Di Carlo E; Musiani P; Forni G; Fradelizi D; Nanni P; Lollini PL
Gene Ther; 2001 Nov; 8(22):1698-704. PubMed ID: 11892837
[TBL] [Abstract][Full Text] [Related]
50. T cell-mediated tumor rejection displays diverse dependence upon perforin and IFN-gamma mechanisms that cannot be predicted from in vitro T cell characteristics.
Peng L; Krauss JC; Plautz GE; Mukai S; Shu S; Cohen PA
J Immunol; 2000 Dec; 165(12):7116-24. PubMed ID: 11120842
[TBL] [Abstract][Full Text] [Related]
51. Different tumours, transduced with different cytokine genes as G-CSF and IL-2, show inhibition of tumour take through neutrophil activation but differ in T cell functions.
Stoppacciaro A; Forni G; Colombo MP
Folia Biol (Praha); 1994; 40(1-2):89-99. PubMed ID: 7525363
[TBL] [Abstract][Full Text] [Related]
52. CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model.
Espenschied J; Lamont J; Longmate J; Pendas S; Wang Z; Diamond DJ; Ellenhorn JD
J Immunol; 2003 Mar; 170(6):3401-7. PubMed ID: 12626601
[TBL] [Abstract][Full Text] [Related]
53. IL-21 enhances tumor rejection through a NKG2D-dependent mechanism.
Takaki R; Hayakawa Y; Nelson A; Sivakumar PV; Hughes S; Smyth MJ; Lanier LL
J Immunol; 2005 Aug; 175(4):2167-73. PubMed ID: 16081783
[TBL] [Abstract][Full Text] [Related]
54. T cell infiltration into class II MHC-disparate allografts and acute rejection is dependent on the IFN-gamma-induced chemokine Mig.
Koga S; Auerbach MB; Engeman TM; Novick AC; Toma H; Fairchild RL
J Immunol; 1999 Nov; 163(9):4878-85. PubMed ID: 10528189
[TBL] [Abstract][Full Text] [Related]
55. Targeted delivery of murine IFN-gamma using a recombinant fowlpox virus: NK cell recruitment to regional lymph nodes and priming of tumor-specific host immunity.
Zeytin H; Reali E; Zaharoff DA; Rogers CJ; Schlom J; Greiner JW
J Interferon Cytokine Res; 2008 Feb; 28(2):73-87. PubMed ID: 18279103
[TBL] [Abstract][Full Text] [Related]
56. Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin.
Sacchi A; Gasparri A; Curnis F; Bellone M; Corti A
Cancer Res; 2004 Oct; 64(19):7150-5. PubMed ID: 15466213
[TBL] [Abstract][Full Text] [Related]
57. Helper-independent, L-selectinlow CD8+ T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression.
Peng L; Kjaergaard J; Plautz GE; Weng DE; Shu S; Cohen PA
J Immunol; 2000 Nov; 165(10):5738-49. PubMed ID: 11067932
[TBL] [Abstract][Full Text] [Related]
58. Antiangiogenic and antitumor activities of IL-27.
Shimizu M; Shimamura M; Owaki T; Asakawa M; Fujita K; Kudo M; Iwakura Y; Takeda Y; Luster AD; Mizuguchi J; Yoshimoto T
J Immunol; 2006 Jun; 176(12):7317-24. PubMed ID: 16751375
[TBL] [Abstract][Full Text] [Related]
59. Immunobiology of allograft rejection in the absence of IFN-gamma: CD8+ effector cells develop independently of CD4+ cells and CD40-CD40 ligand interactions.
Bishop DK; Chan Wood S; Eichwald EJ; Orosz CG
J Immunol; 2001 Mar; 166(5):3248-55. PubMed ID: 11207279
[TBL] [Abstract][Full Text] [Related]
60. Enhanced cell-mediated cytotoxicity by interferon-gamma and interleukin-2 against syngeneic murine mammary adenocarcinoma.
Nakajima I; Chu TM
Mol Biother; 1992 Mar; 4(1):47-52. PubMed ID: 1627274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
